Henagliflozin for blood sugar stability and immune aging in diabetes
Part of Hormones & metabolism clinical trials.
This study tests a new diabetes pill called henagliflozin to see if it helps smooth out blood sugar ups and downs and may also slow aging of the immune system in people with type 2 diabetes who are already on insulin. It is for adults aged 50–70 whose blood sugar is still high despite insulin therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes for at least 6 months and are between 50 and 70 years old.
- Your blood sugar is not well controlled (HbA1c above 8%) even though you use insulin.
- You have a body mass index (BMI) of 20 or higher.
- You have not used certain other diabetes drugs (SGLT2 inhibitors or GLP-1 agonists) in the last 3 months.
- You do not have serious kidney, liver, or heart problems, or recent infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination pill (henagliflozin and metformin) compared to metformin alone in people recently diagnosed with type 2 diabetes. The goal is to see which treatment works better and is safer.
This study tests if ganagliflozin, a once-daily pill, can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and manage blood sugar.
This trial tests whether a combination of two diabetes medicines, henagliflozin and metformin, can improve body composition (fat and muscle) in older adults new to diabetes treatment. It may help you better manage blood sugar and body weight.
This study tests how safe and effective the diabetes medication henagliflozin is for Chinese patients with type 2 diabetes. It is an observational study, meaning you will continue your regular care while researchers watch your progress.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Hear when a new Diabetes Mellitus, Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.